Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
Japan’s fourth Avastin (bevacizumab) biosimilar by Nippon Kayaku will join the NHI price list on November 16 along with a host of new kit products and dosage forms. This wraps up biosimilar listings for FY2022, meaning that no biologic follow-on…
To read the full story
Related Article
- Sotyktu, Spevigo, Fintepla, Koselugo, and More Now Available in Japan
November 17, 2022
REGULATORY
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- MHLW Simplifies Repatha Optimal Use Guidelines
October 5, 2026
- No Financial Aid Planned for OTC-Like Drug Charge System Changes: Ueno
October 5, 2026
- Leustatin Label to Warn Against Breastfeeding for 7 Days after Treatment
October 5, 2026
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…